June 1, 2015

#NoMakeupMonday, Break Up With Your Makeup Contest, & Cetaphil + SelfieStick Giveaway!

My #NoMakeupMonday selfie, unedited and no filter

Its #NoMakeupMonday, and that means ditching the makeup and going bare-faced for a day! I love the concept, and it’s something I do multiple times a week. Even though it seems that all I talk about on my blog and YouTube channel is makeup, I love sharing natural beauty inspiration. Whether I wear just a hint of makeup to enhance my natural features, or go completely makeup-free, I love giving my skin a break every few days. Recently I spent almost a week over the Memorial Day holiday with family on the lake. I didn’t wear makeup the entire time and it was so refreshing. My skin got a little sun and was glowing! The day I returned I applied my regular makeup, and I felt like the texture of my skin looked off, almost unnatural. No matter if your skin is clear or not, nothing looks better than your natural glow. Having a good skincare regime and a healthy diet are essential for glowing skin.

I wanted to share the newest contest from Galderma, the makers of Cetaphil, and inspire you to “Break Up With Your Makeup” as well! You can win an all-inclusive trip to the 2015 NY Film Festival just by submitting your no-makeup selfie using #BreakUpWMakeup, and share how you stay confident on “tough skin days”. The submissions are accepted until June 25th. Details of the contest are included in the infographic at the end of this post.

I’m also hosting a giveaway for y’all! Enter using the form below (click here if form is not displayed), and win a Cetaphil gift pack + a selfie stick:

a Rafflecopter giveaway

Good luck!

More ▼

X Close

IMPORTANT SAFETY INFORMATION:

Important Safety Information – Soolantra® Cream

Indication: SOOLANTRA® (ivermectin) Cream, 1%, is indicated for the treatment of inflammatory lesions of rosacea. Adverse Events: In clinical trials with SOOLANTRA® Cream, the most common adverse reactions (incidence ≤1 %) included skin burning sensation and skin irritation. Warnings / Precautions: Not for oral, ophthalmic or intravaginal use.

Important Safety Information – Mirvaso® Gel*

Indication Mirvaso® (brimonidine) topical gel, 0.33% is an alpha-2 adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions ( ≥1%) included erythema, flushing, skin-burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

*Each gram of gel contains 5mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base

Important Safety Information – Oracea® Capsules

Indication: ORACEA® (doxycycline, USP) 40 mg** Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (≥2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

**30 mg immediate release & 10 mg delayed release beads

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

♥ Check out my latest video ♥

–Barkbox Unboxing May 15

♥ YOUTUBE: http://www.youtube.com/GlamMeUp8

♥ DESIGN WEBSITE: http://www.glammedupdesigns.com

♥ TWITTER: http://www.twitter.com/GlamMeUp

♥ EMAIL: [email protected]

♥ FACEBOOK: http://www.facebook.com/GlamMeUp8

♥ GOOGLE+: http://plus.google.com/+GenaM

♥ INSTAGRAM: http://www.instagram.com/glammeup

♥ PINTEREST: http://www.pinterest.com/GlamMeUp